Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug market with Pomalyst (pomalidomide) long after it should have faced competition from generic alternatives.
Pomalyst is a prescription medicine, taken along with dexamethasone, used to treat adults with multiple myeloma who have previously received at least two medicines to treat multiple myeloma.
In a legal complaint submitted in a Manhattan federal court, Blue Cross ...